A university that has held a longstanding monopoly as the sole institution federally licensed to cultivate marijuana for research has confirmed the termination of its partnership with the National Institute on Drug Abuse (NIDA). According to Jacob Batte, the director of news and media relations at the University of Mississippi, “NIDA has chosen not to award the current year task order to the University of Mississippi for cannabis production.”
Batte added that the university has two years remaining on its federal contract and is ready to utilize its extensive experience in cannabis research—spanning over 57 years—to advance the field and address any future needs NIDA may have.
Shifts in Cannabis Research Partnerships
Mahmoud ElSohly, who has led the university’s cannabis cultivation and research division as part of NIDA’s drug supply program, declined to provide further comment on the situation. This cancellation was first reported by Cannabis Wire, which noted that although Ole Miss’s government contract for cannabis production is active until 2028, NIDA informed the university that it would not be placing any new orders.
Historically, the University of Mississippi has held a monopoly on the production of research-grade cannabis. However, the landscape is changing; there are now seven Drug Enforcement Administration (DEA)-approved bulk marijuana growers. This expansion follows increasing calls from legislators and public health experts for a more comprehensive study of cannabis.
Last year, a study from Ole Miss indicated that the cannabis produced at the university closely resembles products available on lawful state markets. However, some researchers have expressed skepticism regarding quality and THC potency, citing past complaints.
Implications for Future Research
NIDA’s decision to cease orders from Ole Miss follows the cancellation of a separate contract by the Trump administration’s Department of Government Efficiency (DOGE) that monitored cannabinoid content in confiscated cannabis. ElSohly stated that his lab might continue to operate without interruption until federal funding resumes, though the end of sample flow could halt a longstanding history of THC level monitoring in the illicit cannabis market.
Despite these cuts, the University of Mississippi remains committed to cannabis research, with Batte asserting that the UM School of Pharmacy will continue to lead in cannabis innovation and discovery through various initiatives, including the National Center for Natural Products Research and the National Center for Cannabis Research and Education.
Earlier this year, the National Institutes of Health (NIH) launched the Resource Center for Cannabis and Cannabinoid Research, located at Ole Miss, in collaboration with Washington State University and the United States Pharmacopeia. This initiative aims to provide interactive resources, webinars, and funding opportunities to facilitate evidence-based research.
The DEA has recently increased recruitment efforts, inviting individuals from diverse backgrounds to assist in the “war on drugs,” signaling a shift in priorities as the cannabis conversation evolves.
Calls for reform are echoing within research communities as studies indicate the need for further investigation into cannabis. Experts have highlighted that existing government restrictions hinder scientific exploration, with authors from the University of Maryland emphasizing that cannabis’s classification as a Schedule I substance stifles research potential.
As legalization progresses, researchers argue that regulatory reform is crucial to bridging the evidence gap in cannabis science and meeting public demand.